Updated Jan 26, 2018

China’s blockbuster biotechnology week

Two cloned macaques named Zhong Zhong and Hua Hua at the non-human-primate research facility under the Chinese Academy of Sciences (CAS). Photo: Xinhua / Jin Liwang via Getty Images

Two biotechnology stories from China captured the world’s attention this past week:

  • First, the WSJ reported that a group of doctors in Hangzhou have been using CRISPR gene-editing in experiments with cancer patients. Elsewhere, medical scientists are far more cautious about using the technology in humans.

The concern: Clinical trials are not always well regulated around the world. The gene editing activity in China not only flouts the safety-first standard in developed countries and exploits desperate patients, it misses an opportunity to learn from carefully designed clinical trials.

  • Second, more than two decades after Dolly the sheep was cloned, scientists in China reported they had cloned the first primate. It required new techniques and involved dozens of failures before two infant monkeys were finally born with perfect copies of the genes in their cells, creating enormous opportunities for comparative research.

What it means: These results reinforce the possibility of using human clones for research. Still, the risks involved in cloning for human reproduction are simply too great, as the many failed attempts at monkey cloning make clear.

The bottom line: These developments are a reminder that the U.S. is no longer the sole player. However, science is not a zero-sum game. Along with the need for appropriate regulation, the question now is whether the U.S. is in a position to collaborate and contribute new information. In that sense, the less flashy National Institutes of Health announcement of a $190 million commitment to support work on new tools for gene editing is ultimately the bigger news this week.

Jonathan D. Moreno is the David and Lyn Silfen University Professor of Ethics at the University of Pennsylvania.

Go deeper

Updated 2 mins ago - Politics & Policy

Coronavirus dashboard

Photo Illustration: Sarah Grillo/Axios. Photos: Noam Galai, Jamie McCarthy, Josep Lago/AFP, Alfredo Estrella/AFP, and Narayan Maharjan/NurPhoto, all via Getty Images

  1. Global: Total confirmed cases as of 5 a.m. ET: 6,181,781 — Total deaths: 372,136— Total recoveries — 2,646,874Map.
  2. U.S.: Total confirmed cases as of 5 a.m. ET: 1,790,191 — Total deaths: 104,383— Total recoveries: 444,758 — Total tested: 16,936,891Map.
  3. Public health: Black Americans' competing crisesCoronavirus looms over George Floyd protests across the country.
  4. 2020: AIPAC conference in March 2021 canceled.
  5. Economy: What U.S. workplaces may look like next — Both part of America's unfinished businessFuture of mobility in post-pandemic world.
  6. World: Former FDA commissioner says "this is not the time" to cut ties with WHO — White House sends 2 million doses of hydroxychloroquine to Brazil, 1,000 ventilators to come.

Your guide to comparing climate change and coronavirus

Illustration: Eniola Odetunde/Axios

Climate change and the coronavirus have a lot more in common than the letter C, but their differences explain society’s divergent responses to each.

Why it matters: The Internet is full of comparisons, some from biased perspectives. I'm going to try to cut through the noise to help discerning readers looking for objective information.

Updated 1 min ago - Politics & Policy

George Floyd protests: Unrest continues for 6th night across U.S.

A protest near the White House on Sunday night. Photo: Alex Wong/Getty Images

Most external lights at the White House were turned off late Sunday as the D.C. National Guard was deployed and authorities fired tear gas at hundreds of protesters nearby, per the New York Times.

What's happening: It's one of several tense, late-night standoffs between law enforcement and demonstrators in the United States.